Helicobacter Pylori Eradication
Conditions
Brief summary
Helicobacter pylori has been recognized as a major pathogen in gastric carcinogenesis. Current guidelines recommend the H. pylori test-and-treat strategy for the purpose of primary and secondary gastric cancer prevention. Considering the point of no return theory, however, H. pylori eradication cannot reduce the risk of gastric cancer in subjects with gastric atrophy and intestinal metaplasia. The intragastric hypoacidic environment is associated with the risk of intestinal-type gastric cancer development. Recently, the secretory ability of the stomach can be measured using the serum pepsinogen (PG) assay.
Detailed description
This study aimed to evaluate the change of serum PGs after H. pylori eradication success and identify the optimal timing of eradication.
Interventions
None listed
Sponsors
Soonchunhyang University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Gastroscopy can be performed * Serologic markers including serum pepsinogen can be measured
Exclusion criteria
* Age \< 20 or \> 70 years * Anemia (serum hemoglobin level \< 10 g/dL) * Severe systemic disease * Advanced chronic liver disease * Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics * History of H. pylori eradication * History of gastric surgery * Recent history of upper gastrointestinal bleeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum pepsinogen change after H. pylori eradication | after 8 weeks | Serum pepsinogen recovery |
Countries
South Korea
Outcome results
None listed